Formycon Plans Ranibizumab Filings With Ustekinumab And Aflibercept In The Wings

Formycon will follow a US filing for ranibizumab before the end of this year with a European submission early in 2020 as it continues work on biosimilar ustekinumab and aflibercept.

Submit
Formycon is gearing up to file its FYB201 ranibizumab biosimilar candidate for approval in the US and the EU • Source: Shutterstock

German biosimilars developer Formycon intends to file its FYB201 ranibizumab candidate with the US Food and Drug Administration by the end of this year after it and marketing partner Bioeq “successfully concluded” a pre-submission meeting with the agency in December 2018. A submission to the European Medicines Agency (EMA) is scheduled for the first quarter of 2020.

“If the submissions progress as planned, marketing authorization approvals in the US and the EU are expected in 2021,” commented...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.